Please use this identifier to cite or link to this item:
|Title:||Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging.|
|Authors:||Hofman, Michael S;Iravani, Amir;Nzenza, Tatenda C;Murphy, Declan G|
|Affiliation:||Department of Cancer Imaging, Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
Austin Health, Heidelberg, Victoria, Australia
|Citation:||The Urologic clinics of North America 2018; 45(3): 503-524|
|Abstract:||Radiolabeled prostate-specific membrane antigen PET (PSMA PET) is emerging as an important modality for imaging prostate cancer (PCa). Promising clinical experience has led to increasing number of studies exploring the role of PSMA PET in different aspects of PCa including primary detection, risk stratification, targeted biopsy, initial staging, restaging at biochemical recurrence, biologic characterization, treatment response assessment and prognostication. PSMA PET may prove an important disease biomarker, expand our understanding of the pathogenesis and pave the way for personalized management of PCa.|
Prostate-specific membrane antigen
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.